Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 24, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: sumatriptan succinate

« Back to Dashboard

sumatriptan succinate Drugs with Tentative Approvals

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Generic Name	NDA	Strength	Dosage Form
Roxane	sumatriptan succinate	078241	EQ 25MG BASE	TABLET;ORAL
Teva Parenteral	sumatriptan succinate	078318	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE;SUBCUTANEOUS
Teva Parenteral	sumatriptan succinate	078318	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE;SUBCUTANEOUS
Watson Labs	sumatriptan succinate	077696	25MG	TABLET; ORAL
Applicant	Generic Name	NDA	Strength	Dosage Form

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.